Phaarmasia Ltd

Phaarmasia Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive grade, reflecting evolving market perceptions amid a challenging pharmaceutical sector. Despite a recent downgrade in its Mojo Grade from Hold to Sell, the company’s valuation metrics suggest a more compelling price entry point relative to its historical averages and peer group, warranting a closer examination for investors seeking micro-cap opportunities in Pharmaceuticals & Biotechnology.

Phaarmasia Limited (NSE: PHAARMASIA, BSE: 523620), a micro-cap pharmaceutical manufacturer specialising in hormonal contraceptive tablets, reported a troubling quarter-on-quarter deterioration in Q4 FY26, posting a net loss of ₹0.70 crores against a profit of ₹16.27 crores in the previous quarter. The Hyderabad-based company, with a modest market capitalisation of ₹53.00 crores, saw its net sales plummet 51.84% sequentially to ₹7.73 crores, raising serious questions about revenue sustainability and operational stability.

Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 09 Feb 2026. While the rating was revised earlier this year, the analysis below reflects the stock’s current fundamentals, returns, and financial metrics as of 29 May 2026, providing investors with an up-to-date view of the company’s position in the Pharmaceuticals & Biotechnology sector.

Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 09 Feb 2026. However, the analysis and financial metrics discussed below reflect the company’s current position as of 18 May 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Phaarmasia Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive grade. This change reflects evolving market perceptions and invites a closer examination of its price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to historical trends and peer benchmarks.

Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 09 Feb 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 05 May 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Phaarmasia Ltd has witnessed a significant improvement in its valuation parameters, shifting from an 'attractive' to a 'very attractive' grade, reflecting a notable change in investor sentiment. Despite a recent 3.5% dip in its share price, the micro-cap pharmaceutical company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now position it favourably against both historical benchmarks and peer averages, signalling potential value opportunities for discerning investors.

Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 09 Feb 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 24 April 2026, providing investors with the latest insights into its performance and outlook.

Phaarmasia Ltd has witnessed a notable improvement in its valuation parameters, shifting from a very attractive to an attractive rating, signalling a renewed price appeal for investors. This micro-cap pharmaceutical player’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios, alongside other key metrics, suggest a more favourable investment proposition compared to its historical averages and peer group benchmarks.

Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 09 February 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 13 April 2026, providing investors with the latest insights into its performance and outlook.

Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 09 February 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 02 April 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 09 February 2026. However, the analysis and financial metrics discussed below reflect the company’s current position as of 16 March 2026, providing investors with the latest insights into its performance and outlook.

Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 09 February 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 05 March 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 09 February 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 21 February 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Phaarmasia Ltd has seen its investment rating upgraded from Sell to Hold, reflecting significant improvements across technical indicators and valuation metrics. The company’s recent financial performance, coupled with a bullish technical outlook and attractive valuation compared to peers, has prompted this reassessment by analysts as of 09 Feb 2026.

Phaarmasia Ltd has witnessed a significant re-rating in its valuation parameters, transitioning from a previously expensive profile to one now deemed attractive by market standards. This shift is underscored by a notable improvement in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to both historical levels and peer benchmarks within the Pharmaceuticals & Biotechnology sector.